Radius Health, Inc. (RDUS)

Market Cap	847.45M
Revenue (ttm)	223.36M -10.2%
Net Income	-68.63M
EPS	-1.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	30.00
Day's Range	n/a
52-Week Range	10.57 - 30.04
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 1, 2025

About RDUS

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Its commercial product includes BINOSTO, TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It also develops abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901)...

• Industry: Steel
• Sector: Materials
• IPO Date: Nov 15, 1993
• Employees: 293
• Stock Exchange: NASDAQ
• Ticker Symbol: RDUS
• Website: https://radiuspharm.com

Financial Performance

In 2021, Radius Recycling's revenue was $229.97 million, a decrease of -3.63% compared to the previous year's $238.65 million. Losses were -$70.18 million, -35.74% less than in 2020.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Data Sources Report a data error